BBSRC/CASE studentship: Determinants of tumour cell sensitivity to PI3K and TOR pathway inhibitors

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

In comparison to normal cells, rapidly dividing tumour cells have greater metabolic demands and re-model their metabolic pathways accordingly to satisfy energy demands. In some cases the tumour cell may actually switch to devouring its own components to satisfy energy demand, a process known as autophagy. Many of the new drugs now entering clinical trials impinge on this autophagy pathway. In this project we aim to investigate how modifying the autophagy pathway influences the tumour cell response to novel chemotherapy drugs.

unavailable